Current Edition


Lilly’s closely watched diabetes drug scores in obesity trial

Dive Brief: Eli Lilly’s experimental diabetes shot tirzepatide helped obese people who have an underlying medical condition lose more than 15% of their body weight …

Continue Reading →

With trial success in kidney disease, Lilly, Boehringer make case for broader use of diabetes drug

Dive Brief: Eli Lilly and Boehringer Ingelheim’s drug Jardiance kept clinical trial participants with kidney disease from needing dialysis or a transplant, the companies announced …

Continue Reading →

Civica targets insulin in effort to produce cheaper drugs

Dive Brief: Civica is making plans to offer three versions of insulin that can be sold at dramatically lower prices than today’s alternatives, targeting a …

Continue Reading →

Lilly’s new eczema drug scores in late-stage studies

Once known primarily for its work in diabetes, Lilly has, for years now, been branching into other areas of drug development like immunology. There, the …

Continue Reading →

In a first, FDA approves an ‘interchangeable’ biosimilar for diabetes

The promise of biosimilars — that competition would bring down the prices of complex biological drugs — hasn’t materialized in the U.S. in the way …

Continue Reading →

Merck inks deal with China’s Xian Janssen for type 2 diabetes drug

China has more than 114 million people living with diabetes, the largest number of any country in the world Global drug giant, Merck signed an …

Continue Reading →